{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T12:57:14Z","timestamp":1648645034957},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"11","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2018,6,27]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> Unintentional passive diffusion of conventional small molecular weight pharmaceuticals\nacross intact membranes of normal healthy cells in tissues and organ systems induces sequelae that limit therapeutic\ndosage and duration of administration. Selective \u201ctargeted\u201d delivery of pharmaceuticals is a molecular\nstrategy that can potentially provide heightened margins-of-safety with greater potency and improved efficacy.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Materials and Methods: <\/jats:title>\n<jats:p>Monophosphate analogs of fludarabine, gemcitabine, and dexamethasone were combined\nwith a carbodiimide reagent in the presence of imidazole to produce reactive intermediates that were subsequently\ncovalently bound to monoclonal anti-IGF-1R or anti-EGFR IgG-immunoglobulin. The resulting covalent\nimmunopharmaceutical end-products, fludarabine-(5'-phosphoramidate)-[anti-IGF-1R], gemcitabine-(5'-\nphosphoramidate)-[anti-IGF-1R], and dexamethasone-(C21-phosphoramidate)-[anti-EGFR] were evaluated by\nSDS-PAGE\/chemiluminescent autoradiography (fragmentation\/polymerization detection), UV spectrophotometric\nabsorbance (purity; molar-incorporation-index), cell-ELISA (retained selective binding-avidity), and cell\nvitality-viability (selectively \u201ctargeted\u201d anti-neoplastic cytotoxicity).\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> Maximum selectively \u201ctargeted\u201d anti-neoplastic cytotoxicity of fludarabine-(5'-phosphoramidate)-[anti-\nIGF-1R], gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R], and dexamethasone-(C21-phosphoramidate)-[anti-\nEGFR] was detected at the pharmaceutical-equivalent concentrations of 10-5 M (94.7%), 10-7 M (93.1%), and 10-7\nM (64.9%) respectively.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>RDiscussion: <\/jats:title>\n<jats:p>\nOrganic chemistry reactions were optimized in a template multi-stage synthesis regimen for fludarabine-(\n5'-phosphoramidate)-[anti-IGF-1R], gemcitabine-(5\u2019-phosphoramidate)-[anti-IGF-1R], and dexamethasone-(\nC21-phosphoramidate)-[anti-EGFR]. Attributes of the synthesis regimen include; [-i-] covalent bonding of\npharmaceutical moeities at high molar incorporation indexes, [-ii-] implementation of organic chemistry reactions\nin a non-dedicated synthesis regimen allowing component substitution and [-iii-] optional preservation of presynthesized\namine-reactive pharmaceutical intermediates for on-demand immunopharmaceutical synthesis. Attributes\nof the covalent immunopharmaceuticals are; absence of any synthetically introduced chemical groups,\nretained IgG-immunoglobulin binding-avidity and potent selective \u201ctargeted\u201d anti-neoplastic cytotoxic potency.\nUnder in-vivo conditions, supplemental anti-neoplastic cytotoxicity is realized through trophic receptor inhibition\nand activation of multiple cytotoxic host immune responses.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612823666171114155439","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T12:17:53Z","timestamp":1530101873000},"page":"1224-1240","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen"],"prefix":"10.2174","volume":"24","author":[{"given":"Cody P.","family":"Coyne","sequence":"first","affiliation":[{"name":"Department of Basic Sciences, College of Veterinary Medicine at Wise Center, Mississippi State University, Mississippi State, Mississippi 39762, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Department of Basic Sciences, College of Veterinary Medicine at Wise Center, Mississippi State University, Mississippi State, Mississippi 39762, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/157156","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/157156\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/157156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T19:49:19Z","timestamp":1608925759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/157156\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,27]]},"references-count":0,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,6,27]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612823666171114155439","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,27]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-06-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}